Werner Lanthaler

Dr Werner Lanthaler (born in 1968, Austrian citizen) was appointed Chief Executive Officer of Evotec on 06 March 2009. His current term will expire on 05 March 2021. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master’s degree from Harvard University and holds a degree in Psychology. Dr Werner Lanthaler serves in the Boards of Directors of AC Immune SA (since July 2018) and argenx SE (since April 2014), where he also serves as Chairman of the Audit Committee. He is also a member of the Supervisory Board of Topas Therapeutics GmbH (since October 2015).

Werner Lanthaler is the CEO at Evotec, based in Europe. With a background in Biotechnology, Werner Lanthaler has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.